A citation-based method for searching scientific literature

Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li, Hongcai Shang, Yaozu Xiang. Protein Cell 2021
Times Cited: 4







List of co-cited articles
24 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
75

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
106
50

The Role of Autophagy in the Heart.
Sebastiano Sciarretta, Yasuhiro Maejima, Daniela Zablocki, Junichi Sadoshima. Annu Rev Physiol 2018
135
50

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.
Joungmok Kim, Mondira Kundu, Benoit Viollet, Kun-Liang Guan. Nat Cell Biol 2011
50

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
96
50

Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Clifford J Bailey. Diabetes Obes Metab 2019
40
50

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
141
50


Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
100
50

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
M J Davies, A Trujillo, U Vijapurkar, C V Damaraju, G Meininger. Diabetes Obes Metab 2015
70
50

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Kristina Striepe, Agnes Jumar, Christian Ott, Marina V Karg, Markus P Schneider, Dennis Kannenkeril, Roland E Schmieder. Circulation 2017
55
50

TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity.
Chao-Yung Wang, Chun-Chi Chen, Mei-Hsiu Lin, Hui-Ting Su, Ming-Yun Ho, Jih-Kai Yeh, Ming-Lung Tsai, I-Chang Hsieh, Ming-Shien Wen. Biology (Basel) 2020
3
66

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
139
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Brady Barron, Eric Mayoux, R Scott Rector, Adam Whaley-Connell,[...]. Cardiovasc Diabetol 2017
116
50


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Arief Rahadian, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata. J Atheroscler Thromb 2020
16
50

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
488
50

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
125
50

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
466
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
50

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda,[...]. Diabetes Care 2019
20
50

Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Stephanie Lankhorst, Mariëtte H W Kappers, Joep H M van Esch, Frank M M Smedts, Stefan Sleijfer, Ron H J Mathijssen, Hans J Baelde, A H Jan Danser, Anton H van den Meiracker. Hypertension 2014
54
25

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami. Diabetes Obes Metab 2019
15
25

Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.
Vivek Narayan, Stephen Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman,[...]. Clin Cancer Res 2017
36
25

Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.
Vishnu Chintalgattu, Meredith L Rees, James C Culver, Aditya Goel, Tilahu Jiffar, Jianhu Zhang, Kenneth Dunner, Shibani Pati, James A Bankson, Renata Pasqualini,[...]. Sci Transl Med 2013
109
25

An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells.
Zipeng Xie, Fang Wang, Lingqiang Lin, Shaoxian Duan, Xiangyang Liu, Xiaoyu Li, Ting Li, Mei Xue, Ying Cheng, He Ren,[...]. Cancer Lett 2020
3
33

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
Chang Myung Oh, Sungsoo Cho, Ji Yong Jang, Hyeongseok Kim, Sukyung Chun, Minkyung Choi, Sangkyu Park, Young Guk Ko. Korean Circ J 2019
22
25

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
116
25

Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.
Fabian Jacob, Amina Y Yonis, Friederike Cuello, Pradeep Luther, Thomas Schulze, Alexandra Eder, Thomas Streichert, Ingra Mannhardt, Marc N Hirt, Sebastian Schaaf,[...]. PLoS One 2016
25
25

Autophagy and autophagy-related proteins in the immune system.
Shusaku T Shibutani, Tatsuya Saitoh, Heike Nowag, Christian Münz, Tamotsu Yoshimori. Nat Immunol 2015
278
25

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.
Risto Kerkela, Kathleen C Woulfe, Jean-Bernard Durand, Ronald Vagnozzi, David Kramer, Tammy F Chu, Cara Beahm, Ming Hui Chen, Thomas Force. Clin Transl Sci 2009
158
25

Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats.
Veysel Özgür Barış, Berk Dinçsoy, Esra Gedikli, Ayşen Erdemb. Kardiol Pol 2021
2
50

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S Rosen, Beatrice Seddon, Suayib Yalcin, Hans Gelderblom, Charles C Williams, Elena Fumagalli,[...]. Cancer 2015
52
25

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J Lenihan, Gregory Y H Lip, Alexander R Lyon,[...]. Eur Heart J 2016
914
25

Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
Lindsay DeVorkin, Matthew Hattersley, Paul Kim, Jenna Ries, Jaeline Spowart, Michael S Anglesio, Samuel M Levi, David G Huntsman, Ravi K Amaravadi, Jeffrey D Winkler,[...]. Mol Cancer Res 2017
33
25

Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Prakash C Thakur, Jennifer L Miller-Ocuin, Khanh Nguyen, Rina Matsuda, Aatur D Singhi, Herbert J Zeh, Nathan Bahary. J Transl Med 2018
22
25

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Gideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, Shenghui Tang, Rajeshwari Sridhara, Anthony Murgo, Robert Justice, Richard Pazdur. Oncologist 2012
64
25

Doppler estimation of reduced coronary flow reserve in mice with pressure overload cardiac hypertrophy.
Craig J Hartley, Anilkumar K Reddy, Sridhar Madala, Lloyd H Michael, Mark L Entman, George E Taffet. Ultrasound Med Biol 2008
41
25

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T Kim,[...]. N Engl J Med 2007
25

Methods in mammalian autophagy research.
Noboru Mizushima, Tamotsu Yoshimori, Beth Levine. Cell 2010
25


Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla. CA Cancer J Clin 2016
195
25

SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).
Keith R Laderoute, Joy M Calaoagan, Peter B Madrid, Anthony E Klon, Paula J Ehrlich. Cancer Biol Ther 2010
30
25

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
Matheus Dyczynski, Yasmin Yu, Magdalena Otrocka, Santiago Parpal, Tiago Braga, Aine Brigette Henley, Henric Zazzi, Mikael Lerner, Krister Wennerberg, Jenny Viklund,[...]. Cancer Lett 2018
35
25

SQSTM1/p62 loss reverses the inhibitory effect of sunitinib on autophagy independent of AMPK signaling.
Bolin Hou, Gang Wang, Quan Gao, Yanjie Wei, Caining Zhang, Yange Wang, Yuqing Huo, Huaiyi Yang, Xuejun Jiang, Zhijun Xi. Sci Rep 2019
9
25

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
Umberto Campia, Javid J Moslehi, Laleh Amiri-Kordestani, Ana Barac, Joshua A Beckman, David D Chism, Paul Cohen, John D Groarke, Joerg Herrmann, Carolyn M Reilly,[...]. Circulation 2019
57
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.